Fulvestrant Injection– An Anti-cancer Drug,CAS No.: 129453-61-8, Bulk and Injection (PFS): 250mg in 5ml

Introduction:

Cancer is a dreadful disease that affects millions of lives worldwide. The search for an effective anti-cancer drug has been an ongoing process for decades. Fulvestrant Injection, also known as Faslodex, is one such drug that has gained a lot of attention in recent times because of its effectiveness in treating breast cancer. Fulvestrant Injection is a selective estrogen receptor down-regulator that is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women who have been previously treated with other anti-estrogen medications.

Product Description:

The Fulvestrant Injection is a potent and selective estrogen receptor down-regulator that is used to treat hormone receptor-positive metastatic breast cancer. It is an anti-estrogen medication that works by blocking the effects of estrogen in breast tissue. The medication is available in both bulk and injection forms, with a CAS No. of 129453-61-8.

The injection is provided in pre-filled syringes (PFS) containing 250mg of Fulvestrant in 5ml. The injection is administered intramuscularly into the buttocks, and it is given once every two weeks for the first three doses, and thereafter once every four weeks until disease progression or unacceptable toxicity.

Merchants' Benefits:

Merchants looking to distribute Fulvestrant Injection can benefit in several ways:

1. Highly Effective Drug:

Fulvestrant Injection is a highly effective drug that has been shown to improve patient outcomes. Clinical studies have demonstrated that Fulvestrant Injection us effective compared to other anti-cancer drugs, such as tamoxifen or anastrozole, for the treatment of hormone receptor-positive metastatic breast cancer.

2. Increased Demand for Breast Cancer Treatment:

The incidence of breast cancer is increasing globally, and there is a growing demand for effective breast cancer treatments. As a result, there is an increasing need for Fulvestrant Injection.

3. Competitive Pricing:

Compared to other anti-cancer drugs, Fulvestrant Injection is competitively priced. This makes it an appealing option for merchants who are looking to offer affordable cancer treatments to patients.

4. High-Quality Production:

As a manufacturer located in China, producing Fulvestrant Injection under strict pharmaceutical manufacturing standards, you can ensure your customers receive a high-quality product that is thoroughly tested and properly regulated.

Conclusion:

Fulvestrant Injection is a highly effective and competitively priced anti-cancer drug that has demonstrated its effectiveness in treating hormone receptor-positive metastatic breast cancer. Because of the increasing incidence of breast cancer globally, there is a growing need for effective treatments such as Fulvestrant Injection. As a manufacturer, you can offer a high-quality product that adheres to strict pharmaceutical manufacturing standards, ensuring your customers receive a top-of-the-line product that meets their needs. By offering competitive pricing, you can attract merchants looking to offer affordable cancer treatments to patients, ultimately benefiting both the patients and your business.

DESCRIPTION

Fulvestrant Injection for intramuscular administration is an estrogen receptor antagonist. The chemical name is 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)-triene-3,17-beta-diol. The molecular formula is C32H47F5O3S and its structural formula is:.

Fulvestrant, USP is a white powder with a molecular weight of 606.77. The sterile injection solution is a clear, colorless to yellow viscous liquid supplied in two 5 mL single-dose prefilled syringes each containing 250 mg/5 mL of fulvestrant, USP for intramuscular administration.

Fulvestrant Injection contains the following inactive ingredients in each 5 mL syringe: benzyl alcohol 500 mg

(10% w/v) and dehydrated alcohol 500 mg (10% w/v); castor oil 3000 mg (60% w/v), medium chain triglycerides q.s. to 5 mL (10.8% w/v), and nitrogen q.s.

Mechanism of Action

Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen. Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.

In vitro studies demonstrated that fulvestrant is a reversible inhibitor of the growth of tamoxifen-resistant, as well as estrogen-sensitive human breast cancer (MCF-7) cell lines. In in vivo tumor studies, fulvestrant delayed the establishment of tumors from xenografts of human breast cancer MCF-7 cells in nude mice. Fulvestrant inhibited the growth of established MCF-7 xenografts and of tamoxifen-resistant breast tumor xenografts. Fulvestrant showed no agonist-type effects in in vivo uterotrophic assays in immature or ovariectomized mice and rats. In in vivo studies in immature rats and ovariectomized monkeys, fulvestrant blocked the uterotrophic action of estradiol. In postmenopausal women, the absence of changes in plasma concentrations of FSH and LH in response to fulvestrant treatment (250 mg monthly) suggests no peripheral steroidal effects.

Pharmacodynamics

In a clinical study in postmenopausal women with primary breast cancer treated with single doses of Fulvestrant Injection 15 to 22 days prior to surgery, there was evidence of increasing down-regulation of ER with increasing dose. This was associated with a dose-related decrease in the expression of the progesterone receptor,

an estrogen-regulated protein. These effects on the ER pathway were also associated with a decrease in Ki67 labeling index, a marker of cell proliferation.

Name: Fulvestrant

Fulvestrant is a prescription medicine used to treat advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic).

Dosage: Injection

Specification

250mg: 0.5ml

Indications

Monotherapy

Fulvestrant is indicated for the treatment of:

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or

HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.

Focusing on the corporate mission of "taking genetic engineering as the guide and contributing to human health", we insist on serving the Chinese market as the main body and supporting some foreign markets as a supplementary layout. Jiuyuan Marketing cultivates a professional, dedicated and enterprising pharmaceutical service team, and establishes a stable, credible and efficient pharmaceutical service network, focusing on the crystallization of scientific research, quality control, and production-high-quality medical equipment products are delivered to urgent needs in time Of patients, and are used safely, effectively, economically and operated efficiently.

It is our constant pursuit to improve professional pharmacy service skills, expand the radiation capacity of pharmacy service network, and make Jiuyuan medical equipment products better serve human health.

The sales network covers more than 30 provinces and cities across the country,

The industrial territory continues to expand and is exported to Asia,

South America, Europe, Africa and many other countries.

Company Honor

National New High-tech Enterprise

Key New High-tech Enterprise of National Torch Plan

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center

Zhejiang Provincial Enterprise Technology Center

Zhejiang Famous Trademark

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

FAQ

Q: What is your term of payment?

A: 30% down payment before producing and 70% balance payment before shipping.

Q: Which payment form you can accept?

A: T/T, Western Union, PayPal etc. We accept any convenient and swift payment term.

Q: Which certificate do you have?

A: GMP, EUGMP and ISO14001.

Q: Do you have the test and audit service?

A: Yes, we can assist to get the designated test report for product and the designated factory audit report.

Q: What's is your shipping service?

A: We can provide services for vessel booking, goods consolidation, customs declaration, shipping documents preparation and delivery bulk at the shipping port.

Why choose us?

• At our Chinese factory, we have the expertise and technology to produce outstanding Oncology Injection products.
• We focus on the challenges and pressures that customers care about, and solve technical problems in the application of Fulvestrant Injection– An Anti-cancer Drug,CAS No.: 129453-61-8, Bulk and Injection (PFS): 250mg in 5ml for customers.
• Our customer-centric approach means that we offer flexibility in our Oncology Injection products, allowing our clients to modify their orders quickly and easily.
• In the spirit of 'design first, keep improving', we will further strengthen management, optimize structure and expand scale.
• Our clients' satisfaction is our top priority, and we strive to build long-lasting relationships through excellent Oncology Injection products and services.
• We will work together to make our company stronger, better and bigger, and ultimately achieve green and sustainable development.
• We strive to keep our pricing competitive without compromising on the quality of our Oncology Injection products.
• We concentrate on regional advantages, brand advantages, technological advantages and human resources advantages to enhance the independent innovation capabilities and market competitiveness of corporate brands and products.
• We use premium quality raw materials to produce Oncology Injection products that are safe, reliable, and long-lasting.
• We look forward to build a long-term cooperation with your business.

Hot Tags: fulvestrant injection– an anti-cancer drug,cas no.: 129453-61-8, bulk and injection (pfs): 250mg in 5ml, China fulvestrant injection– an anti-cancer drug,cas no.: 129453-61-8, bulk and injection (pfs): 250mg in 5ml manufacturers, suppliers, factory, cancer supply injection, oncology sales injection, cancer retail injection, oncology manufacturer injection, cancer packaging injection, cancer therapy injection